Prostate Cancer Incidence, Mortality Rates Mainly Stable, Decreasing
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Dec. 11, 2024 -- In most countries, prostate cancer incidence and mortality rates decreased or were stable in the most recent five-year period, but increasing trends were seen in some countries, according to a study published online Dec. 11 in European Urology.
Elizabeth J. Schafer, M.P.H., from the American Cancer Society in Atlanta, and colleagues examined worldwide patterns and trends in prostate cancer incidence and mortality using data from the Cancer Incidence in Five Continents series and the World Health Organization mortality database.
The researchers found that the estimated prostate cancer rates varied 13-fold for incidence and 9.5-fold for mortality across regions in 2022, with the highest incidence rates seen in Australia/New Zealand, North America, Northern Europe, and Latin America and the Caribbean, and the highest mortality rates seen in sub-Saharan Africa and Latin America and the Caribbean. During the most recent five-year period, incidence and mortality rates increased in 11 of 50 countries and nine of 59 countries included in the study, respectively, mostly in Africa, Asia, Latin America and the Caribbean, and Central and Eastern Europe. In 38 countries, there were decreases observed in mortality rates, mainly in Europe, Oceania, and Latin America and the Caribbean.
"These findings reinforce the need for improvements in access to early detection and treatment services to mitigate the undue high burden of the disease in these countries," the authors write. "Furthermore, improvements in data availability and quality, particularly in low- and middle-income countries in Asia and Africa, will enhance our understanding of current disparities and prioritization of early detection and treatment approaches."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted December 2024
Read this next
Study Compares Benefits, Harms of Treatments for Chronic Hives
WEDNESDAY, July 23, 2025 -- Omalizumab and remibrutinib may be the most effective treatments for reducing hives, itch, and swelling with chronic urticaria, according to a study...
USPSTF Guidelines of Little Value for Estimating Preeclampsia Risk in Those at Moderate Risk
WEDNESDAY, July 23, 2025 -- Moderate U.S. Preventive Services Task Force (USPSTF) preeclampsia risk factors have little value for estimating the risk for preeclampsia, according...
Endocrine Society, July 12-15
The annual meeting of the Endocrine Society (ENDO 2025) was held from July 12 to 15 in San Francisco, attracting more than 7,000 participants, including clinicians, academicians...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.